STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia
ConclusionsThese data establish the critical role of a newly discovered BCR independent Ca2+ entry in CLL evolution, provide new insights into CLL pathophysiology, and support innovative therapeutic perspectives such as targeting STIM1 located at the plasma membrane.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Calcium | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Immunotherapy | Leukemia | Rituxan | Study